1. Home
  2. PNNT vs TRML Comparison

PNNT vs TRML Comparison

Compare PNNT & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNNT
  • TRML
  • Stock Information
  • Founded
  • PNNT 2007
  • TRML 2021
  • Country
  • PNNT United States
  • TRML United States
  • Employees
  • PNNT N/A
  • TRML N/A
  • Industry
  • PNNT Finance: Consumer Services
  • TRML Biotechnology: Pharmaceutical Preparations
  • Sector
  • PNNT Finance
  • TRML Health Care
  • Exchange
  • PNNT Nasdaq
  • TRML Nasdaq
  • Market Cap
  • PNNT 459.4M
  • TRML 509.8M
  • IPO Year
  • PNNT 2007
  • TRML N/A
  • Fundamental
  • Price
  • PNNT $7.17
  • TRML $12.21
  • Analyst Decision
  • PNNT Hold
  • TRML Strong Buy
  • Analyst Count
  • PNNT 2
  • TRML 6
  • Target Price
  • PNNT $6.00
  • TRML $54.00
  • AVG Volume (30 Days)
  • PNNT 436.5K
  • TRML 344.8K
  • Earning Date
  • PNNT 02-10-2025
  • TRML 03-18-2025
  • Dividend Yield
  • PNNT 12.97%
  • TRML N/A
  • EPS Growth
  • PNNT 11.30
  • TRML N/A
  • EPS
  • PNNT 0.83
  • TRML N/A
  • Revenue
  • PNNT $143,689,000.00
  • TRML N/A
  • Revenue This Year
  • PNNT N/A
  • TRML N/A
  • Revenue Next Year
  • PNNT N/A
  • TRML N/A
  • P/E Ratio
  • PNNT $8.62
  • TRML N/A
  • Revenue Growth
  • PNNT N/A
  • TRML N/A
  • 52 Week Low
  • PNNT $6.43
  • TRML $12.12
  • 52 Week High
  • PNNT $8.04
  • TRML $48.31
  • Technical
  • Relative Strength Index (RSI)
  • PNNT 54.56
  • TRML 25.27
  • Support Level
  • PNNT $7.10
  • TRML $12.13
  • Resistance Level
  • PNNT $7.25
  • TRML $14.58
  • Average True Range (ATR)
  • PNNT 0.09
  • TRML 0.84
  • MACD
  • PNNT 0.00
  • TRML -0.05
  • Stochastic Oscillator
  • PNNT 70.69
  • TRML 1.79

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About TRML Tourmaline Bio Inc.

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Share on Social Networks: